This is our third and final article, showcasing the excellent scientists that have successfully secured large network grants
MS Research Australia’s fundraising campaign, Kiss Goodbye to MS, is going from strength to strength. With a 2016
The Chief Executive Officer of MS Research Australia, Dr Matthew Miles, was thrilled to be one of the
The American Food and Drug Administration (FDA) has approved OCREVUSâ„¢ (ocrelizumab) for the treatment of both relapsing and
Gadolinium is a chemical that is known as a ‘contrast agent’, meaning that it shows up in X-rays
People with progressive neurodegenerative diseases in the NDIS Ten national peak not-for-profit health organisations making up the Neurological
The old rules around (a) who holds the information and (b) what avenues do I have to go
MS Research Australia’s latest grant funding round has committed funding to a number of projects aimed at developing
MS Research Australia is delighted to announce a further $1.5 million in research funding commencing in 2017. The
